# Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

> **NCT00712881** · PHASE2 · COMPLETED · sponsor: **Cephalon, Inc.** · enrollment: 126 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Liposomal doxorubicin hydrochloride
- **DRUG:** Cyclophosphamide
- **DRUG:** Trastuzumab
- **DRUG:** Free doxorubicin hydrochloride
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00712881
- **Lead sponsor:** Cephalon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-13
- **Primary completion:** 2015-09-17
- **Final completion:** 2015-09-17
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00712881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00712881, "Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00712881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*